Prof. Antonio Costanzo is the Dermatology Unit Director in Humanitas Research Hospital. He graduated with his MD degree in Medicine and Surgery from the University of Rome, La Sapienza in 1994. He then went on to complete post-graduate study and received a speciality degree in Internal Medicine in 1999 and a Dermatology speciality degree in 2006.
Medical areas of interest:
Previous experience:
Research areas of interest:
His clinical research is focused on the characterization of the activity of biologics in psoriasis and psoriatic arthritis. This research is strictly linked to basic research activity on the pathogenesis of psoriasis and on the use of pharmacogenetic approach to predict the efficacy and safety of biologics in psoriasis.
In the past, Professor Costanzo has collaborated to the characterization of basic mechanisms of TNF inflammatory signalling in epithelial cells and NFkappaB regulation by different stimuli. More recently his research group has collaborated to the discovery of IL-21 as critical mediator of keratinocyte proliferation in psoriasis. Professor Costanzo has authored or co-authored more than 120 publications in internationally peer-reviewed journals.
Teaching experience: Full Professor of Dermatology at Humanitas University
Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=Costanzo+A
Read more
Dr. Sogol Nasrollahzadeh is a medical doctor with more than 8-year experience in the private practice.
In 2020, Sogol graduated from the Faculty of Medicine of the Giresun University in Turkey. Although she completed her studies, Dr. Nasrollahzadeh continues to receive training and to attend university courses in plastic surgery and skin disease related studies. After graduating, Sogol commenced working at the Ozel Bower Hospital, one of the leading private hospitals in Turkey. Over a period of 3 years after her degree, Sogol not only perfected her studies in cosmetic and aesthetic medical field, but also, she performed several successful procedures in treating dermatological diseases and regenerative treatments with a specific focus on anti-aging solutions.
Sogol has successfully completed additional studies obtaining an international certification and license in mesotherapy and regenerative medicine. In 2023, she set up her clinic in the center of Istanbul where, together with another doctor, patients can receive regenerative medicine treatments and skin disease related therapies as well as plastic surgery assistance. The clinic commenced to collaborate with Advanced Bio-Gen in order to provide a set of additional stem cells treatments for several medical conditions.
Sogol is usually described by her patients as a professional with high moral and human qualities, characterized by empathy, integrity, and compassion. Her dedication to the well-being of others is reflected in her ability for active listening and empathy towards patients. Sogol demonstrates strong morality in addressing sensitive issues and respects the privacy of patients with great ethical consideration. Dr. Nasrollahzadeh is known for her sincerity, transparency, and respect towards colleagues and collaborators. Her integrity is evident in the honest management of situations and adherence to the highest professional standards. Her leadership is team-oriented, fostering a collaborative and inclusive work environment.
Read moreExperience
2016 - 2022
ISTANBUL MEDIPOL UNIVERSITY
2010 - 2016
BEZM-I ÂLEM FOUNDATION UNIVERSITY
2010 - 2015
Bezmialem Vakif University Faculty of Medicine
2009 - 2010
Bagcilar Training and Research Hospital
2009 - 2010
ISTANBUL BAGCILAR TRAINING AND RESEARCH HOSPITAL
1997 - 2009
ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL
1997 - 2009
Haseki Training and Research Hospital
Education
2016
BEZM-I ÂLEM FOUNDATION UNIVERSITY, DEPARTMENT OF ANESTHESIOLOGY AND REANIMATION
1997
Istanbul Haseki Training and Research Hospital, Anesthesiology and Reanimation
1993
ISTANBUL HASEKI TRAINING AND RESEARCH HOSPITAL, Medical Specialization
1989
Istanbul University, Faculty of Medicine
1983
ISTANBUL UNIVERSITY, CERRAHPAŞA FACULTY OF MEDICINE, FACULTY OF MEDICINE
Read moreDoctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |
Experience
2018 - 2022
Health Sciences University – Şişli Hamidiye Etfal Training and Research Hospital
2016 - 2018
Diyarbakır Memorial Dicle Hospital Cardiology Clinic
2010 - 2010
Dicle University Faculty of Medicine, Department of Cardiology
2010 - 2016
Private Veni Vidi Hospital, Cardiology Clinic Supervisor
2006 - 2010
Dicle University Faculty of Medicine, Department of Cardiology
2005 - 2006
Urfa State Hospital
1999 - 2005
Turkey High Specialization Training and Research Hospital
1998 - 1999
Duruca Health Center
Education
2018
Health Sciences University, Cardiology
2010
Dicle University, Department of Cardiology
2005
Cardiology Turkey High Specialization Training and Research Hospital, Medical Specialization
1998
Ege University, Faculty of Medicine
Read moreDoctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |
Experience
2019 - 2022
University of Health Sciences, Faculty of Medicine, Ankara City Hospital, Cardiology Clinic, Ankara
2017 - 2019
University of Health Sciences, Faculty of Medicine, Turkey Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,
2012 - 2017
Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,
2012 - 2017
T.R. Karabük University, Faculty of Medicine, Department of Cardiology
2006 - 2006
Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,
2001 - 2006
Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,
1996 - 2001
Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic, Ankara,
Education
2017 Karabük University, Faculty of Medicine, Department of Cardiology
2006 Türkiye Higher Specialization Training and Research Hospital, Cardiology Clinic
2001 Türkiye Higher Specialization Training and Research Hospital, Ankara, Cardiology
1996 Ankara University, Faculty of Medicine
Read moreDoctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |
PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Read more
Doctor's visit | price on request |
Umbilical сord blood treatment | $7000 - $9000 |